CAPR - Capricor Therapeutics Stock Price, News & Analysis

$2.10 -0.01 (-0.47 %)
(As of 11/22/2017 04:00 PM ET)
Previous Close$2.11
Today's Range$2.08 - $2.19
52-Week Range$0.63 - $4.25
Volume249,986 shs
Average Volume1.04 million shs
Market Capitalization$53.99 million
P/E RatioN/A
Dividend YieldN/A
Beta-3.58

About Capricor Therapeutics (NASDAQ:CAPR)

Capricor Therapeutics logoCapricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapeutics. The Company focuses on discovering, developing and commercializing regenerative medicine and large molecule products for the treatment of disease, with a primary focus on the treatment of cardiovascular diseases, including orphan indications. Its product candidate, CAP-1002, a cardiosphere-derived cell product, is being tested in the ALLSTAR Phase II clinical study on patients having suffered a myocardial infarction (MI), while the DYNAMIC clinical study is testing CAP-1002 in patients in the advanced-stage of heart failure. CAP-1002 is also being tested in the HOPE-Duchenne Phase I/II clinical study for use in connection with Duchenne muscular dystrophy-related cardiomyopathy. Cenderitide, a dual receptor natriuretic peptide agonist, is being tested in a Phase II clinical study. Exosomes are nano-sized, membrane-enclosed vesicles.


Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:CAPR
  • Previous Symbol: NASDAQ:NLTX
  • CUSIPN/A

    Debt

    Debt-to-Equity RatioN/A
    Current Ratio0.91%
    Quick Ratio0.91%

    Price-To-Earnings

    Trailing P/E RatioN/A
    Forward P/E RatioN/A
    P/E GrowthN/A

    Sales & Book Value

    Annual Sales$4 million
    Price / Sales13.50
    Cash FlowN/A
    Price / CashN/A
    Book Value($0.17) per share
    Price / Book-12.35

    Dividend

    Annual DividendN/A
    Dividend YieldN/A

    Profitability

    Trailing EPS($0.66)
    Net Income$-18,800,000.00
    Net Margins-464.56%
    Return on EquityN/A
    Return on Assets-82.11%

    Miscellaneous

    Employees40
    Outstanding Shares25,710,000

    Frequently Asked Questions for Capricor Therapeutics (NASDAQ:CAPR)

    What is Capricor Therapeutics' stock symbol?

    Capricor Therapeutics trades on the NASDAQ under the ticker symbol "CAPR."

    How were Capricor Therapeutics' earnings last quarter?

    Capricor Therapeutics, Inc. (NASDAQ:CAPR) released its quarterly earnings data on Wednesday, November, 8th. The biotechnology company reported ($0.12) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.07. The biotechnology company earned $0.31 million during the quarter, compared to the consensus estimate of $1 million. The business's revenue was down 58.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.29) EPS. View Capricor Therapeutics' Earnings History.

    Where is Capricor Therapeutics' stock going? Where will Capricor Therapeutics' stock price be in 2017?

    2 Wall Street analysts have issued 1-year target prices for Capricor Therapeutics' stock. Their forecasts range from $2.15 to $6.50. On average, they anticipate Capricor Therapeutics' stock price to reach $4.33 in the next twelve months. View Analyst Ratings for Capricor Therapeutics.

    Are investors shorting Capricor Therapeutics?

    Capricor Therapeutics saw a increase in short interest in October. As of October 13th, there was short interest totalling 1,577,570 shares, an increase of 26.5% from the September 29th total of 1,247,225 shares. Based on an average daily trading volume, of 3,845,022 shares, the days-to-cover ratio is currently 0.4 days. Approximately 14.0% of the company's stock are short sold.

    Who are some of Capricor Therapeutics' key competitors?

    Who are Capricor Therapeutics' key executives?

    Capricor Therapeutics' management team includes the folowing people:

    • Frank I. Litvack M.D., Independent Executive Chairman of the Board (Age 59)
    • Linda Marban Ph.D., President, Chief Executive Officer, Director (Age 51)
    • Leland J. Gershell M.D. Ph.D., Chief Financial Officer, Principal Financial Officer (Age 44)
    • Karen G. Krasney J.D., Executive Vice President, General Counsel (Age 62)
    • Anthony Bergmann, Principal Accounting Officer, Vice President - Finance (Age 29)
    • Thomas Lyle Copmann Ph.D., Vice President - Regulatory Affairs and Drug Development (Age 61)
    • Houman Hemmati M.D., Ph.D., Vice President - Medical & Clinical Development, New Therapies
    • Luis Rodriguez-Borlado Ph.D., Vice President - Regenerative Therapies
    • Rachel Smith Ph.D., Vice President - Research & Development (Age 36)
    • Deborah Ascheim M.D., Chief Medical Officer

    Who owns Capricor Therapeutics stock?

    Capricor Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Belpointe Asset Management LLC (0.32%), Jane Street Group LLC (0.25%) and Wells Fargo & Company MN (0.14%). Company insiders that own Capricor Therapeutics stock include Anthony Bergmann, Karen Krasney, Leland Gershell, Linda Marban, Louis J Grasmick, Louis Manzo and Sinai Medical Center Cedars. View Institutional Ownership Trends for Capricor Therapeutics.

    Who bought Capricor Therapeutics stock? Who is buying Capricor Therapeutics stock?

    Capricor Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Belpointe Asset Management LLC, Jane Street Group LLC and Wells Fargo & Company MN. Company insiders that have bought Capricor Therapeutics stock in the last two years include Anthony Bergmann, Karen Krasney, Leland Gershell, Linda Marban, Louis J Grasmick, Louis Manzo and Sinai Medical Center Cedars. View Insider Buying and Selling for Capricor Therapeutics.

    How do I buy Capricor Therapeutics stock?

    Shares of Capricor Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

    What is Capricor Therapeutics' stock price today?

    One share of Capricor Therapeutics stock can currently be purchased for approximately $2.10.

    How big of a company is Capricor Therapeutics?

    Capricor Therapeutics has a market capitalization of $53.99 million and generates $4 million in revenue each year. The biotechnology company earns $-18,800,000.00 in net income (profit) each year or ($0.66) on an earnings per share basis. Capricor Therapeutics employs 40 workers across the globe.

    How can I contact Capricor Therapeutics?

    Capricor Therapeutics' mailing address is 8840 Wilshire Blvd Fl 2, BEVERLY HILLS, CA 90211-2606, United States. The biotechnology company can be reached via phone at +1-310-3583200 or via email at [email protected]


    MarketBeat Community Rating for Capricor Therapeutics (CAPR)

    Community Ranking:  2.2 out of 5 (star star)
    Outperform Votes:  91 (Vote Outperform)
    Underperform Votes:  113 (Vote Underperform)
    Total Votes:  204
    MarketBeat's community ratings are surveys of what our community members think about Capricor Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

    Analyst Ratings

    Analysts' Consensus Rating for Capricor Therapeutics (NASDAQ:CAPR)

      (How are Consensus Ratings Calculated?)
    Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 2 Buy Ratings, 0 Strong Buy Ratings
    Consensus Rating:Buy (Score: 3.00)
    Consensus Price Target: $4.33 (105.95% upside)

    Consensus Price Target History for Capricor Therapeutics (NASDAQ:CAPR)

    Price Target History for Capricor Therapeutics (NASDAQ:CAPR)

    Analysts' Ratings History for Capricor Therapeutics (NASDAQ:CAPR)

    Show:
    DateFirmActionRatingPrice TargetImpact on Share PriceDetails
    9/15/2017HC WainwrightBoost Price TargetBuy -> Buy$2.15 -> $6.50N/AView Rating Details
    7/22/2017Rodman & RenshawReiterated RatingBuy$2.15N/AView Rating Details
    10/20/2016Roth CapitalSet Price TargetBuy$12.00N/AView Rating Details
    (Data available from 11/22/2015 forward)

    Earnings

    Earnings History and Estimates Chart for Capricor Therapeutics (NASDAQ:CAPR)

    Earnings by Quarter for Capricor Therapeutics (NASDAQ:CAPR)

    Earnings History by Quarter for Capricor Therapeutics (NASDAQ CAPR)

    DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
    11/8/2017Q3 2017($0.19)($0.12)$1.00 million$0.31 millionViewN/AView Earnings Details
    8/10/2017Q2 2017($0.18)($0.16)$1.10 million$1.00 millionViewN/AView Earnings Details
    5/15/2017Q1 2017($0.15)($0.17)$0.87 million$0.88 millionViewN/AView Earnings Details
    3/15/2017Q4 2016($0.30)($0.14)$1.05 million$0.91 millionViewN/AView Earnings Details
    11/10/2016Q316($0.27)($0.29)$1.12 million$0.75 millionViewN/AView Earnings Details
    8/15/2016Q2($0.24)($0.26)$1.22 million$1.13 millionViewListenView Earnings Details
    5/12/2016Q116($0.19)($0.26)$1.10 million$1.22 millionViewListenView Earnings Details
    3/17/2016Q415($0.19)($0.21)$1.10 million$1.12 millionViewN/AView Earnings Details
    11/12/2015Q315($0.26)($0.18)$1.10 million$1.32 millionViewN/AView Earnings Details
    8/13/2015Q215($0.26)($0.19)$1.10 million$1.29 millionViewN/AView Earnings Details
    5/12/2015Q1 2015($0.14)($0.23)$1.10 million$1.79 millionViewN/AView Earnings Details
    3/18/2015Q4 2014($0.14)($0.16)$1.30 million$1.40 millionViewN/AView Earnings Details
    11/13/2014Q3 2014($0.22)($0.13)$1.30 millionViewN/AView Earnings Details
    (Data available from 1/1/2011 forward)

    Estimates

    Earnings Estimates for Capricor Therapeutics (NASDAQ:CAPR)
    Current Year EPS Consensus Estimate: $-0.7 EPS
    Next Year EPS Consensus Estimate: $-0.76 EPS

    Dividends

    Dividend History for Capricor Therapeutics (NASDAQ:CAPR)
    No dividend announcements for this company have been tracked by MarketBeat.com

    Insider Trades

    Insider Trading and Institutional Ownership History for Capricor Therapeutics (NASDAQ CAPR)

    Insider Ownership Percentage: 28.50%
    Institutional Ownership Percentage: 3.09%
    Insider Trades by Quarter for Capricor Therapeutics (NASDAQ:CAPR)
    Institutional Ownership by Quarter for Capricor Therapeutics (NASDAQ:CAPR)

    Insider Trades by Quarter for Capricor Therapeutics (NASDAQ CAPR)

    Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
    5/9/2017Louis ManzoDirectorBuy10,000$3.10$31,000.00View SEC Filing  
    5/9/2017Sinai Medical Center CedarsMajor ShareholderBuy1,145,161$3.10$3,549,999.10View SEC Filing  
    9/21/2016Sinai Medical Center CedarsMajor ShareholderBuy312,500$3.20$1,000,000.00View SEC Filing  
    3/16/2016Anthony BergmannVPBuy2,030$2.40$4,872.00View SEC Filing  
    3/16/2016Karen KrasneyEVPBuy4,060$2.40$9,744.00View SEC Filing  
    3/16/2016Leland GershellCFOBuy2,100$2.40$5,040.00View SEC Filing  
    3/16/2016Linda MarbanCEOBuy10,152$2.40$24,364.80View SEC Filing  
    3/16/2016Louis J GrasmickDirectorBuy91,369$2.40$219,285.60View SEC Filing  
    3/16/2016Sinai Medical Center CedarsMajor ShareholderBuy416,666$2.40$999,998.40View SEC Filing  
    8/20/2015Louis J. GrasmickDirectorBuy11,900$4.11$48,909.00View SEC Filing  
    8/19/2015Eduardo Marbanmajor shareholderBuy18,400$4.36$80,224.00View SEC Filing  
    1/21/2015Joshua A KazamDirectorBuy7,096$3.52$24,977.92View SEC Filing  
    1/21/2015Sinai Medical Center CedarsMajor ShareholderBuy851,546$3.52$2,997,441.92View SEC Filing  
    (Data available from 1/1/2013 forward)

    Headlines

    Latest Headlines for Capricor Therapeutics (NASDAQ CAPR)

    Source:

    Social Media

    Financials

    Chart

    Capricor Therapeutics (NASDAQ CAPR) Chart for Wednesday, November, 22, 2017
    Loading chart…

    This page was last updated on 11/22/2017 by MarketBeat.com Staff

    Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.